The Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) previously reported increased mortality in patients who sustained a periprocedural stroke or cardiac event (myocardial infarction [MI] or biomarker only) in follow-up to 4 years. We now extend these observations to 10 years.
T
he Carotid Revascularization Endarterectomy Stenting Trial (CREST) randomized patients to receive either carotid stenting (CAS) or endarterectomy (CEA), with a primary study outcome, including any cerebrovascular accident (CVA), myocardial infarction (MI), or death during a periprocedural period and subsequent ipsilateral stroke over follow-up extending to 10 years. 1, 2 The study demonstrated that patients with a periprocedural stroke 3 or cardiac event (MI or biomarker only) 4 are at increased risk of death. However, the median follow-up duration for this report was only 2.5 years, and we did not assess how the excess risk of death varied over time or mortality causation.
The long-term temporal pattern of the risk of death associated with periprocedural stroke or cardiac events has profound implications. It is expected that there will be an increased risk of death in the immediate period surrounding periprocedural complications. The relative magnitude of this increase in mortality for stroke versus cardiac events provides an index of the relative clinical importance of the event; however, a stroke or cardiac event may also be associated with a persistent increased risk of death extending over years of follow-up. This increased long-term risk could arise from a stroke or cardiac event causing permanent damage to brain or myocardium (respectively) as the now compromised organ could be more susceptible to processes leading to death over a multiyear horizon. Alternatively, the occurrence of a stroke or cardiac event could simply be a marker identifying a subpopulation with underlying disease that places the patient at increased risk of death (irrespective of the acute periprocedural event). If the risk of death is clustered in the immediate period after the event, then the management of the patient should focus on the prevention and clinical management of the proximate event. Alternatively, should there be a long-term increased risk of death, the clinical management as well needs to take a long-term approach in managing both the sequela of the event and potential underlying chronic processes that place the patient at higher risk. To address these unresolved questions, we used 10-year data from the CREST trial to investigate the association between periprocedural events and long-term prognosis after carotid artery revascularization. Furthermore, we sought to examine the temporal occurrence of deaths after periprocedural complications and to perform subspecific analysis of mortality to provide additional insight into the mechanisms of death after complications and into the prevention and management of these complications.
METHODS
CREST is a randomized controlled trial with blinded end point adjudication that was designed to compare the outcomes of CAS versus CEA for up to 4 years after randomization. One hundred seventeen centers in North America enrolled 2502 patients between December 2000 and July 2008. The institutional review board of each participating center approved the protocol. 1 All patients gave informed consent. The original protocol was amended to allow follow-up to 10 years with institutional review board approval, as well as informed reconsent of study patients at each center. 2 The current report uses a per-protocol (as treated) approach to focus on the risk of death after stroke or cardiac events associated with CAS or CEA procedures. Accordingly, all 2272 patients who received their assigned treatment within 30 days after randomization and who had no occurrence of stroke or cardiac events between randomization and the index CAS or CEA are included in this analysis. Eligibility criteria, detailed statistical analysis, and short-as well as longterm results in reference to the study's primary end point have been previously reported. 1, 2 Stroke was defined as an acute neurological event with focal symptoms and signs of at least 24-hour duration that were consistent with focal cerebral ischemia or hemorrhage. A stroke was considered periprocedural if it occurred within 30 days of an index CAS or CEA. The stroke adjudication process was initiated by clinical sites and mediated by the CREST stroke adjudication committees. Details surrounding the determination of stroke occurrence, type, and severity are described elsewhere. 3 MI, by CREST protocol, required elevation of troponin or CK-MB to a value of ≥2× the individual center's laboratory upper limits of normal, plus either electrocardiographic evidence of an MI or symptoms consistent with
WHAT IS KNOWN
• CREST (Carotid Revascularization Endarterectomy versus Stenting Trial) reported a mortality risk, extending for up to 4 years of follow-up, for patients who sustained a periprocedural stroke or cardiac event (myocardial infarction or biomarker only) after carotid revascularization with carotid endarterectomy or carotid stenting.
WHAT THE STUDY ADDS
• In follow-up to 10 years, both periprocedural stroke and cardiac events were predictive of increased mortality.
• The risk of death after periprocedural stroke was high during 90-day follow-up but essentially the same as noted in patients without stroke from 91 days to 10 years.
• The risk of death after periprocedural cardiac events was lower than that of stroke during 90-day follow-up; however, this risk continued to increase from 91 days to 10 years.
• As cardiac-related death is common in the late period after both periprocedural myocardial infarction and biomarker-only events, an opportunity to reduce long-term mortality by abating late events through the identification of patients sustaining periprocedural events and the evaluation of these patients for ischemic heart disease is suggested.
an MI. All cardiac events were considered to be periprocedural if they occurred within 30 days of an index CAS or CEA. Cardiac biomarkers were measured routinely before and 6 to 8 hours after the assigned study procedure. Evidence of myocardial ischemia included symptoms consistent with ischemia or ECG evidence of myocardial ischemia. In the absence of ischemic symptoms or ECG changes, elevation of biomarkers only was a prespecified event termed a biomarker-only event. The threshold for biomarker elevation was increased to ≥3× the upper limit of normal after coronary intervention and ≥5× the upper limit of normal after coronary bypass surgery. All suspected MI and biomarker-only events were adjudicated by the CREST MI Adjudication Committee. Details describing the diagnosis of protocol MI and biomarker-only events are described elsewhere. 4 Source documentation and case report forms associated with reported deaths during the 10-year follow-up period were reviewed by a single medical professional to classify the cause of death as neurological (stroke was identified as the primary cause of death), cardiac (primary cause of death is directly related to cardiovascular disease, such as acute MI, sudden cardiac death syndrome, heart failure), or other (death cases where stroke or heart disease were not identified as the primary cause of death).
Statistical Analysis
For the purposes of this analysis, the variables of interest were periprocedural stroke and periprocedural cardiac events (protocol MI and biomarker only). Baseline characteristics are summarized as mean±SD for continuous variables and counts/ proportions for categorical variables. Continuous variables were compared by t test or 1-way ANOVA whereas categorical variables were compared by χ 2 . Kaplan-Meier estimates for all-cause mortality stratified by stroke and cardiac events (both protocol MI and biomarker only) were calculated, and survival curves plotted. We used proportional hazards models (adjusted for age, sex, symptomatic status of the artery, and assigned treatment group) to estimate the association between periprocedural events and subsequent mortality.
In addition to models that incorporated the full follow-up period, separate models were fit using data only from the first 90 days of follow-up and from 91 days to 10 years. The latter models excluded any patients who died, had events, or withdrew during the initial 90 days. The 90-day threshold was selected to include a sufficient total number of deaths to provide stable estimates of treatment differences but without regard to the number of events in each treatment arm. Subspecific causes of death were also reported by time interval grouping.
The data, analytic methods, and study materials will be made available on request to other researchers for purposes of reproducing the results or replicating the procedure.
RESULTS
CREST randomized a total of 2502 patients with 1240 assigned to CEA and 1262 to CAS. Of the 2274 patients who received their assigned treatment within 30 days of randomization, 2 patients had a stroke after randomization but before the index carotid revascularization and were excluded, leaving 2272 patients for the current analysis. Long-term mortality data are reported in this group of patients with a median follow-up of 7.5 years (interquartile range, 4.0-8.9). There were 580 deaths, 293 in the CEA group and 287 in the CAS group with no difference in long-term mortality by treatment group (hazard ratio [HR]=0.96; 95% CI, 0.81-1.12; P=0.58).
A total of 69 patients had a periprocedural stroke, 37 patients a periprocedural MI, and 19 patients a biomarker-only event. Baseline patient characteristics for the stroke and cardiac event groups are shown in Table 1 . Patients with periprocedural stroke were older (72.1±8.4 versus 68.8±8.8 years; P=0.002), more likely to have had treatment of a symptomatic artery (71.1% versus 52.6%; P=0.003), and had higher systolic blood pressure at study The temporal pattern of long-term risk for mortality was substantially different among patient groups.
For patients sustaining a periprocedural stroke, the risk of death during the first 90 days was remarkably high (HR=14.41; 95% CI, 5.33-38.94; P<0.0001; Table 2 ). This early risk after periprocedural stroke is reflected in Kaplan-Meier curves as an initial plummet in the curve describing stroke mortality (Figure 1 ). After the first 90 days, however, mortality risk in the stroke cohort decreased (HR=1.40; 95% CI, 0.93-2.10; P=0.11; Table 2 ) as reflected in the relatively parallel KaplanMeier curves between 91 days and 10 years (Figure 1 ).
For patients with a periprocedural protocol MI (HR=8.20; 95% CI, 1.86-36.2; P=0.006) or a biomarker-only event (HR=8.44; 95% CI, 1.09-65.5; P=0.04), the 90-day risk of death was also markedly elevated but to a lesser degree than in patients with stroke. Specifically, the risk of death at 90 days for those who sustained a periprocedural stroke was 1.9× greater than the risk for those with a periprocedural proto- Kaplan-Meier curves describing mortality risk for stroke, the curves describing both protocol MI and biomarkeronly events continue to diverge for 10-year follow-up in a pattern consistent with ongoing risk (Figure 2 ; Table 2 ). For MI, the risk of excess mortality from 91 days to 10 years was elevated by 240% (HR=3.40; 95% CI, 2.09-5.53; P<0.0001). For biomarker-only events, there was a suggestive but nonsignificant association with higher 91-day to 10-year risk (HR=1.88; 95% CI, 0.97-3.64; P=0.06). The test of differences between the risk of death for those experiencing a protocol MI versus a biomarker-only event was not significant for the entire 10-year period (P=0.05), nor for the early period (P=0.98), or for the long-term period (P=0.15).
Causes of death for patients with stroke and cardiac events were noted to follow temporal patterns as well.
At 0 to 90 days, all deaths in the periprocedural stroke and protocol MI groups were neurological. The single early death in the biomarker-only group in this early time frame was cardiac.
In the late (91 days to 10 years) time frame, for patients with periprocedural stroke who died, the cause of death was neurological in 3 of 25 (12%), cardiac in 13 (52%), and other in 9 (36%). For patients with periprocedural protocol MI who died in the late period, the cause was neurological in 1 of 17 (6%), cardiac in 8 (47%), and other in 9 (47%). Similarly, for patients with biomarker-only events, late deaths were neurological in 1 of 9 (11%), cardiac in 4 (44%), and other in 4 (44%). Hence, for both cardiac event cohorts, mortality from 91 days to 10 years is nearly equally divided between cardiac and other causes with only ≈10% of deaths because of a neurological cause. For the entire 10-year period, cardiac deaths compromise 42% of deaths after protocol MI, 50% of deaths after biomarker-only events, and 41% of deaths after stroke (Table 2) .
DISCUSSION
In CREST, the largest randomized trial comparing CEA to CAS in both symptomatic and asymptomatic patients to date, the occurrence of periprocedural stroke, MI, or a biomarker-only event portended significantly higher mortality in the long-term, up to 10 years. The temporal pattern varied by event, brain compared with heart. As anticipated, the excess mortality hazard was highest for all 3 events during the first 90 days after the procedure: stroke (HR=14.41; 95% CI, 5.33-38.94), MI (HR=8.20; 95% CI, 1.86-36.2), and biomarkeronly events (HR=8.44; 95% CI, 1.09-65.5). In contrast, beyond 90 days, excess long-term mortality persisted for those with MI (HR=3.30; 95% CI, 2.09-5.53; P=0.0001) and approached a significant difference for biomarker-only events (HR=1.88; 95% CI, 0.97-3.64; P=0.06); however, the late period elevation in longterm mortality for stroke was not significant (HR=1.40; 95% CI, 0.98-2.10; P=0.11).
The temporal divergence of risk for death after periprocedural stroke compared with MI has several implications. In CREST, there were significantly more strokes in the CAS cohort than in the CEA cohort. The difference in the risk of death between those with and without a periprocedural stroke was largely driven by the difference in deaths within 90 days, where the death risk curves were relatively parallel after that point (Figure 1 ). These data suggest that the opportunity to attenuate long-term mortality associated with stroke is mostly dependent on the reduction of periprocedural stroke and that the opportunity to reduce stroke is particularly open to a reduction in CAS-related stroke.
Stroke prevention should begin with patient selection. Patients with visible carotid lesion thrombus, heavy lesion calcification, and complex arch and carotid anatomy are at an increased risk of stroke after CAS placement. 5 In addition, a recent report from CREST demonstrated a stroke rate after CAS equal to that after CEA if patients with longer and complex lesions are excluded from CAS treatment. 6 Thus, easily identifiable lesion characteristics may identify patients who would best be treated with CEA rather than CAS. Newer stent designs, 7 proximal protection, 8 and carotid flow reversal 9 may potentially improve CAS-related complications while operator training as well as close attention to aggressive medical treatment remain important for both revascularization modalities. 10 For those patients in whom periprocedural stroke cannot be prevented, new endovascular methods for acute treatment may limit brain injury. 11 Because delay must be minimized for such treatments to be effective, careful patient assessment with the National Institutes of Health Stroke Scale before and during the hours after the procedure might be beneficial, especially in patients who may manifest subtle neurological deficits that may not be readily apparent while the effects of anesthesia or sedation linger. Emergency neurological consultation and urgent brain imaging may be used to establish a diagnosis in equivocal cases.
Beyond 90 days, the risk of death for those with periprocedural stroke was not significantly different compared with those without stroke with the proportion of neurological and non-neurological causes of death also similar in patients with and without periprocedural stroke. Of those deaths, 52% of those with a periprocedural stroke were from cardiac causes, compared with 32% of those without a periprocedural stroke being from cardiac causes (Table 2) . Accordingly, it would also seem prudent to evaluate these patients for heart disease per current guidelines and to pursue best medical management of vascular risk per current guideline measures. 12 The association of periprocedural cardiac events with long-term mortality is less straightforward because of the presence of 2 prespecified components in the cardiac event group (protocol MI and biomarker only) and the ongoing late separation of Kaplan-Meier curves between 91 days and 10 years in cardiac-event group ( Figure 2) . As with stroke, the recognition of cardiac events is a sine qua non for efforts to attenuate their effects. The identification of the biomarker-only group is clearly of paramount importance as, by definition, this group is defined by only an abnormal laboratory value (cardiac marker) in the absence of chest pain or ECG changes. As biomarker-only patients make up ≈1/3 of cardiac event patients, failure to identify this subpopulation of patients, best done by troponin measurement no earlier than 6 to 8 hours post-procedure, would result in the failure to identify a significant number of the patients at risk.
In CREST, there were significantly fewer MIs in the stent cohort group than in the endarterectomy cohort. All early deaths in the protocol MI group were neurological because they were in the stroke cohort while the single death in the biomarker-only groups was cardiac. Compared with stroke, patients with cardiac events were also at increased risk for mortality to 10 years. Unlike periprocedural stroke, the difference in the 10-year risk of death among patients with MI (compared with those without an MI) was attributable to both: (1) an initial risk difference that was substantial but still more modest than for those with/without a periprocedural stroke, and (2) a higher persistent risk of death extending over the remainder of the follow-up period (Figure 2 ). This resulted in a modest initial separation, but with the risk of death curves continuing to diverge after the 90-day period.
Some caution is encouraged about the risk difference after biomarker-only events compared with stroke events. Although the relative risk of late mortality for the biomarker-only group is higher at 1.8 as compared with the relative risk of 1.4 for mortality in the stroke group, it is reasonable to argue that the postprocedural risk for these 2 type of events does not differ because the CIs are similar and the risk factor modification is different for the 2 groups in terms of revascularization. In addition, the postprocedure risk of the biomarker-only events does not differ from the risk in the protocol MI group (P=0.15). We have taken the position that the postprocedural risk after either type of cardiac event is likely elevated, whereas there is less evidence of elevation in the postprocedural risk after stroke; however, it is clear that alternative interpretations of these differences are possible.
Two distinct mechanisms may lead to periprocedural cardiac events. Using current Universal Task Force definitions of MI, 13 it may result from plaque rupture or other mechanisms leading to intimal disruption with thrombus formation (type 1 infarction) or an imbalance in oxygen supply-demand in the presence of stable coronary artery disease (CAD; type 2 infarction). Either mechanism could be applicable to any patient undergoing CEA or CAS.
The term myocardial injury after noncardiac surgery was initially described and defined in the VISION (Vascular Events In Noncardiac Surgery Patients Cohort Evaluation) trial, 14 an international prospective study of >15 000 patients undergoing inpatient noncardiac surgery. After the exclusion of patients with nonischemic troponin elevation (eg, pulmonary emboli, sepsis, and cardioversion), myocardial injury after noncardiac surgery was present in ≈8% of patients studied. Although only 42% of these patients met formal diagnostic criteria for MI, troponin release alone (a biomarker-only event) was also a strong independent predictor of mortality. Other studies have corroborated these find-ings and confirmed that higher troponin values predict higher mortality. [15] [16] [17] [18] [19] [20] [21] Although no large studies have reported the incidence of obstructive CAD in patients with myocardial injury after noncardiac surgery, other studies of troponin release in patients with acute ischemic stroke without concurrent MI have revealed increased mortality at 1 and 3 years. 22 When a group of patients with acute ischemic stroke and cardiac marker release underwent coronary angiography in the TRELAS (Troponin Elevation in Acute Ischemic Stroke) study, these patients were significantly less likely to have coronary culprit lesions than age-and sex-matched patients with non-ST-segment-elevation MIs and similar baseline troponin levels with one half having no angiographic evidence of CAD. 23 Although definitive data on the mechanisms behind periprocedural cardiac events are not available, especially in reference to the presence or absence of culprit coronary lesions, the association of cardiac biomarker elevation and increased mortality risk that may be manifest only by cardiac marker release in these patients is strong and consistent. [14] [15] [16] [17] [18] [19] [20] [21] Understanding the troponin release-mortality connection, it is intuitive to question whether cardiac biomarker release, regardless of mechanism and with or without criteria for MI, is causative of mortality or simply a marker for patients at risk because of underlying cardiac disease. This question cannot be answered from this analysis of CREST data; nevertheless, it is prudent to closely monitor stresses that could require increased myocardial oxygen consumption, such as severe anemia, hypertension, hypotension, persistent tachycardia, or uncompensated heart failure, 18 as well as factors that could predict risk of plaque rupture in the periprocedural time surrounding revascularization procedures. These may include a history suggesting ischemia or an abnormal ischemic study, tachycardia, hypertension, 18 and aspirin 24 or β-blocker withdrawal. 25 It has further been shown that select patients may reduce their risk of periprocedural MI with preoperative coronary revascularization 26 and that perioperative statins may as well be effective in this regard. 27 Although the use of thienopyridines with CEA has not been shown to reduce the risk of MI, their use does appear to be safe suggesting that their empirical use in CEA patients may be reasonable until further studies are done. 28 Strategies to attenuate long-term mortality in these patients are at best hypothetical as mechanisms of biomarker release and even the underlying incidence of obstructive CAD are uncertain. Nonetheless, it seems reasonable to evaluate patients with periprocedural marker release for underlying ischemic heart disease and to treat these patients with medications for the secondary prevention of heart disease as suggested by a recent observational study. 29 Clearly, clinical trials are needed to decide the best management strategy in these high-risk patients.
Differing baseline clinical characteristics between patients who sustain a periprocedural stroke or cardiac event are noted. Although patients with stroke were older, more likely to be hypertensive, and more likely to have a symptomatic lesion than patients with no stroke, only older age was a marker for patients with a higher risk of MI. Because stroke is more common in CAS patients and MI more common in CEA patients, it is tempting to incorporate baseline patient data into patient selection for CEA versus CAS; however, such an approach should be considered speculative only at this time. It nonetheless seems prudent to consider protective strategies to minimize the risk of MI in patients with known CAD or older patients who are at a higher risk for CAD before any intervention, especially if they are selected for CEA. Likewise, caution should be used in using CAS to treat carotid lesions with high-risk lesion or aortic characteristics, especially if the patient is symptomatic.
Limitations
The absolute risks of stroke, MI, and biomarker-only events in this study may seem confounding as they are low; nonetheless, relative risk differences between patients who sustain these complications and those who do not are substantial and statistically valid.
In reference to stroke, brain imaging data were collected when clinically indicated by changes in symptomatic status or neurological function rather than at specific time intervals, and these procedures may have caused an underestimation of stroke. In reference to cardiac events, CREST did not use a central core lab for measurement of biomarkers. The study, therefore, relied on the use of a range of markers and assays with a variation in the definition of an abnormal value. Furthermore, CK+CK-MB only was collected in 30% of the patients and may have been responsible for more CEA patients being sent for adjudication because surgical disruption of skeletal muscle may cause elevation of this biomarker. Differences in length of stay for CAS and CEA procedures may have increased the reporting of cardiac complications in the CEA group because post-8-hour events would have been more likely seen in the treatment group with a longer length of stay.
Conclusions
CREST demonstrated that stroke, MI, and biomarkeronly events are each associated with increased mortality to 10 years.
Although late mortality after periprocedural stroke is largely driven by 90-day neurological events, cardiac events confer a continuous risk of death after 90 days that extend to 10 years.
The identification of patients who are at increased risk because of periprocedural events is central to attempts to attenuate their impact on short-and long-term mortality. This may be especially important in patients with cardiac events, whether through direct causation or their ability to predict a high-risk group, are clearly associated with an increased mortality risk to 10 years. This identification may be challenging, especially in reference to patient who sustain cardiac events as one-third of this cohort can only be identified by routine biomarker determination.
